Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast Cancer
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Alpelisib (Primary) ; Enzalutamide (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 05 Jul 2018 Planned End Date changed from 1 Jun 2021 to 1 Sep 2021.
- 05 Jul 2018 Planned primary completion date changed from 1 Jun 2020 to 1 Sep 2020.
- 05 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Sep 2018.